Pfizer's Sandwich site officially on the block; Acorda gets upgrade on Ampyra sales;

@FiercePharma: Pfizer just might postpone Viagra's patent cliff. News | Follow @FiercePharma

> Pfizer's giant research base at Sandwich, England, has been officially put on the market by CB Richard Ellis following the U.S. drugmaker's decision in February to close the site. Report

> A Citi Investment Research analyst upgraded shares of Acorda Therapeutics, saying the stock is trading at a fair price but could move higher because of strong sales of its Ampyra multiple sclerosis drug. Item

> One year after launching its Bad Ad program--designed to encourage healthcare professionals to report misleading drug promotions--the agency says it's working. Story

> KV Pharmaceutical posted a loss of $174 million in fiscal 2011, compared with a loss of $285.6 million in the prior fiscal year. Article

> Orangetown, NY, may soon approve a settlement of tax challenges by Wyeth Holdings, a subsidiary of Pfizer, over the property assessment of the drug company's Pearl River campus. Piece

> A new meningococcal vaccine just introduced in West Africa has produced very encouraging results, according to the public-private partnership coordinating its distribution. Report

Biotech News

@FierceBiotech: Merck strikes $720M deal with Hanwha for generic Enbrel. Story | Follow @FierceBiotech

@JohnCFierce: The pressure on Forest Labs to do something dramatic has increased considerably today. Wonder what comes next. Follow @JohnCFierce

> E&Y dissects biotech's toughest challenges. Story 

> pSivida forges $169M Pfizer pact for eye drug delivery program. Item 

> For sale: Giant drug research hub. Report 

> Can Biocon get a $1B pharma deal for its oral insulin program? Article

> Array BioPharma axes 70 as it cuts back on discovery work. News 

> Cancer immunotherapies in vogue as specialists seek a "cure." Report 

> Scientists warn on "dead space" as pharma giants shun neuropsych. Story 

Biotech Research News

> Researchers, companies quick to crack E. coli case. News

> The X-Men factor: We inherit 60 mutations from mom and dad. Item

> Three genetic perps fingered for migraine risk. Story

> Complex, spontaneous genetic mutations may be at root of autism. Report

> Scientists often use adult, embryonic stem cells in tandem. News

Manufacturing News

> FDA drives consent decree with H&P/Triad. Story

> Biogen maps way to future factory. Item

> FDA tests nano waters, reorganizes CDER. Article

> DoJ bark may be bigger than bite in Gilead probe. Story 

> Experts: Target distribution for cost savings. News 

> Polish artist uses wooden pallets in his creations. Item 

And Finally... U.S. doctors are too quick to reach for their prescription pads, according to a report urging them to think more about side effects and non-drug alternatives. Report

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.